[1]
|
Rhodes, A., Evans, L.E., Alhazzani, W., et al. (2017) Surviving Sepsis Campaign: International Guidelines for Manage-ment of Sepsis and Septic Shock: 2016. Intensive Care Medicine, 43, 304-377.
https://doi.org/10.1007/s00134-017-4683-6
|
[2]
|
Biehl, M., Ahmed, A., Kashyap, R., Barwise, A. and Gajic, O. (2018) The Incremental Burden of Acute Respiratory Distress Syndrome: Long-Term Follow-Up of a Population-Based Nested Case-Control Study. Mayo Clinic Proceedings, 93, 445-452. https://doi.org/10.1016/j.mayocp.2017.11.025
|
[3]
|
王晓晖, 徐云海, 张波. 毛细血管渗漏指数对脓毒症合并ARDS早期诊断及预后的评估价值[J]. 临床急诊杂志, 2020, 21(5): 350-354.
|
[4]
|
周亮, 谭利平. 线粒体DNA在脓毒症相关性ALI/ARDS发病机制中的作用[J]. 中华危重病急救医学, 2020, 32(2): 253-256.
|
[5]
|
Bellani, G., Laffey, J.G., Pham, T., et al. (2016) Epidemiology,Patterns of Care, and Mortality for Patients with Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA, 315, 788-800.
https://doi.org/10.1001/jama.2016.0291
|
[6]
|
郑永信, 桑岭, 黎毅敏. 脓毒症相关急性呼吸窘迫综合征的研究进展[J]. 临床内科杂志, 2021, 38(9): 580-583.
|
[7]
|
赵春玲, 李玉叶, 王秋义, 等. 脓毒症患者并发急性呼吸窘迫综合征的风险预测列线图模型建立[J]. 中华危重病急救医学, 2023, 35(7): 714-718.
|
[8]
|
Ren, Y., Zhang, L., Xu, F., et al. (2022) Risk Factor Analysis and Nomogram for Predicting In-Hospital Mortality in ICU Patients with Sepsis and Lung Infection. BMC Pulmonary Medicine, 22, Article No. 17.
https://doi.org/10.1186/s12890-021-01809-8
|
[9]
|
罗钰填, 吕常艳, 刘振密, 等. 高迁移率族蛋白1、乳酸及降钙素原对脓毒症患者病情及预后评估价值研究[J]. 创伤与急危重病医学, 2020, 8(5): 322-325.
|
[10]
|
乔良, 刘志. 按柏林新标准分析急诊脓毒症患者发生急性呼吸窘迫综合征的危险因素[J]. 中华危重病急救医学, 2015, 27(7): 558-562.
|
[11]
|
Xie, J.F., Liu, L., Yang, Y., et al. (2018) A Modified Acute Respiratory Distress Syndrome Prediction Score: A Multicenter Cohort Study in China. Journal of Thoracic Disease, 10, 5764-5773. https://doi.org/10.21037/jtd.2018.09.117
|
[12]
|
Cardoso, L.G. and Chiavone, P.A. (2013) The APACHE II Meas-ured on Patients’ Discharge from the Intensive Care Unit in the Prediction of Mortality. Revista Latino-Americana de Enfermage, 21, 811-819.
https://doi.org/10.1590/S0104-11692013000300022
|
[13]
|
Evans, L., Rhodes, A., Alhazzani, W., et al.(2021) Sur-viving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Critical Care Med-icine, 49, e1063-e1143.
|
[14]
|
Ferguson, N.D., Fan, E., Camporota, L., et al. (2012) The Berlin Definition of ARDS: An Expanded Rationale, Justification, and Supplementary Material. Intensive Care Medicine, 38, 1573-1582.
https://doi.org/10.1007/s00134-012-2682-1
|
[15]
|
Poston, J.T. and Koyner, J.L. (2019) Sepsis Associated Acute Kidney Injury. BMJ, 364, k4891.
https://doi.org/10.1136/bmj.k4891
|
[16]
|
Niederman, M.S., Alder, J., Bassetti, M., et al. (2020) Inhaled Amikacin Adjunctive to Intravenous Standard-of-Care Antibiotics in Mechanically Ventilated Patients with Gram-Negative Pneu-monia (INHALE): A Double-Blind, Randomised, Placebo-Controlled, Phase 3, Superiority Trial. The Lancet Infectious Diseases, 20, 330-340.
https://doi.org/10.1016/S1473-3099(19)30574-2
|
[17]
|
Rello, J., Sole-Lleonart, C., Rouby, J.J., et al. (2017) Use of Nebulized Antimicrobials for the Treatment of Respiratory Infections in Invasively Mechanically Ventilated Adults: A Position Paper from the European Society of Clinical Microbiology and Infectious Diseases. Clinical Microbiology and Infection, 23, 629-639.
https://doi.org/10.1016/j.cmi.2017.04.011
|
[18]
|
Kollef, M.H., Ricard, J.D., Roux, D., et al. (2017) A Randomized Trial of the Amikacin Fosfomycin Inhalation System for the Adjunctive Therapy of Gram-Negative Ventilator-Associated Pneumonia: IASIS Trial. Chest, 151, 1239-1246.
https://doi.org/10.1016/j.chest.2016.11.026
|
[19]
|
刘军. 脓毒症免疫调节治疗的共识与争议[J]. 中华医学杂志, 2019, 99(45): 3597-3600.
|
[20]
|
Grübler, M.R., Wigger, O., Berger, D., et al. (2017) Basic Concepts of Heart-Lung In-teractions during Mechanical Ventilation. Swiss Medical Weekly, 147, w14491. https://doi.org/10.4414/smw.2017.14491
|
[21]
|
Pham, T., Brochard, L.J. and Slutsky, A.S. (2017) Mechanical Ven-tilation: State of the Art. Mayo Clinic Proceedings, 92, 1382-1400. https://doi.org/10.1016/j.mayocp.2017.05.004
|
[22]
|
Papafilippou, L., Claxton, A., Dark, P., et al. (2021) Nanotools for Sepsis Diagnosis and Treatment. Advanced Healthcare Materials, 10, e2001378. https://doi.org/10.1002/adhm.202001378
|
[23]
|
章梦丽, 李文强. 脓毒症并发急性呼吸窘迫综合征的治疗策略[J]. 中国急救医学, 2017, 37(10): 883-888.
|
[24]
|
Gattinoni, L., Busana, M., Giosa, L., Macrì, M.M. and Quintel, M. (2019) Prone Positioning in Acute Respiratory Distress Syndrome. Seminars in Respiratory and Critical Care Medicine, 40, 94-100.
https://doi.org/10.1055/s-0039-1685180
|
[25]
|
Guérin, C., Reignier, J., Richard, J.C., et al. (2013) Prone Positioning in Severe Acute Respiratory Distress Syndrome. The New England Journal of Medicine, 368, 2159-2168. https://doi.org/10.1056/NEJMoa1214103
|
[26]
|
Peters van Ton, A.M., Kox, M., Abdo, W.F. and Pickkers, P. (2018) Precision Immunotherapy for Sepsis. Frontiers in Immunology, 9, Article 1926. https://doi.org/10.3389/fimmu.2018.01926
|
[27]
|
刘军. 对脓毒症免疫与炎症关系的思考[C]//中国免疫学会. 第十一届全国免疫学学术大会摘要汇编. 2016: 114.
|
[28]
|
Cawcutt, K.A. and Kalil, A.C. (2019) Saved from Sepsis: Can Immunotherapy Improve Acute and Postacute Outcomes? Critical Care Medicine, 47, 733-735. https://doi.org/10.1097/CCM.0000000000003702
|
[29]
|
Marshall, J.C. (2014) Why Have Clinical Trials in Sepsis Failed? Trends in Molecular Medicine, 20, 195-203.
https://doi.org/10.1016/j.molmed.2014.01.007
|
[30]
|
McElvaney, O.J., Curley, G.F., Rose-John, S. and McElvaney, N.G. (2021) Interleukin-6: Obstacles to Targeting a Complex Cytokine in Critical Illness. The Lancet Respiratory Medicine, 9, 643-654.
https://doi.org/10.1016/S2213-2600(21)00103-X
|
[31]
|
Leentjens, J., Kox, M., Koch, R.M., et al. (2012) Reversal of Immunoparalysis in Humans in Vivo: A Double-Blind, Placebo-Controlled, Randomized Pilot Study. American Journal of Respiratory and Critical Care Medicine, 186, 838-845.
https://doi.org/10.1164/rccm.201204-0645OC
|
[32]
|
Meisel, C., Schefold, J.C., Pschowski, R., et al. (2009) Granu-locyte-Macrophage Colony-Stimulating Factor to Reverse Sepsis-Associated Immunosuppression: A Double-Blind, Randomized, Placebo-Controlled Multicenter Trial. American Journal of Respiratory and Critical Care Medicine, 180, 640-648. https://doi.org/10.1164/rccm.200903-0363OC
|
[33]
|
Hotchkiss, R.S., Colston, E., Yende, S., et al. (2019) Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized Study to Evaluate the Safety, Tolerability, Pharmaco-kinetics, and Pharmacodynamics of Nivolumab. Intensive Care Medicine, 45, 1360-1371. https://doi.org/10.1007/s00134-019-05704-z
|
[34]
|
Delano, M.J. and Ward, P.A. (2016) Sepsis-Induced Immune Dysfunction: Can Immune Therapies Reduce Mortality? Journal of Clinical Investigation, 126, 23-31. https://doi.org/10.1172/JCI82224
|
[35]
|
何超, 王虑, 李文放, 等. 大剂量人血白蛋白快速滴注治疗重度ARDS的临床观察[J]. 中国急救医学, 2011, 31(5): 475-477.
|
[36]
|
Matthy, M.A., Fukuda, N., Frank, J., et al. (2000) Alveo-lar Epithelial Barrier. Role in Lung Fluid Balance in Clinical Lung Injury. Clinics in Chest Medicine, 21, 477-490. https://doi.org/10.1016/S0272-5231(05)70160-X
|
[37]
|
Finfer, S., Bellomo, R., Boyce, N., et al. (2004) A Compar-ison of Albumin and Saline for Fluid Resuscitation in the Intensive Care Unit. The New England Journal of Medicine, 350, 2247-2256. https://doi.org/10.1056/NEJMoa040232
|
[38]
|
Jiang, Z.M., Yang, Q.H. and Zhu, C.Q. (2017) UCP2 in Early Diagnosis and Prognosis of Sepsis. European Review for Medical and Pharmacological Sciences, 21, 549-553.
|
[39]
|
Mantzarlis, K., Tsolaki, V. and Zakynthinos, E. (2017) Role of Oxidative Stress and Mitochondrial Dys-function in Sepsis and Potential Therapies. Oxidative Medicine and Cellular Longevity, 2017, Article ID: 5985209.
https://doi.org/10.1155/2017/5985209
|
[40]
|
张琪. 脓毒症线粒体功能障碍及复苏[J]. 中国小儿急救医学, 2018, 25(7): 507-512.
|
[41]
|
Zhng, Z., Yan, C., Miao, J., et al. (2021) Muscle-Derived Mitochondrial Transplantation Reduces Inflammation, Enhances Bacterial Clearance, and Improves Survival in Sepsis. Shock, 56, 108-118.
https://doi.org/10.1097/SHK.0000000000001681
|
[42]
|
Martin, L., Koczera, P., Zechendorf, E. and Schuerholz, T. (2016) The Endothelial Glycocalyx: New Diagnostic and Therapeutic Approaches in Sepsis. BioMed Research Interna-tional, 2016, Article ID: 3758278.
https://doi.org/10.1155/2016/3758278
|
[43]
|
Anand, D., Ray, S., Srivastava, I.M. and Bhargava, S. (2016) Evolution of Serum Hyaluronan and Syndecan Levels in Prognosis of Sepsis Patients. Clinical Biochemistry, 49, 768-776. https://doi.org/10.1016/j.clinbiochem.2016.02.014
|
[44]
|
应佳云, 陆国平. 内皮细胞表面糖萼在脓毒症中的研究进展[J]. 中华实用儿科临床杂志, 2018, 33(18): 1435-1437.
|
[45]
|
Schött, U., Solomon, C., Fries, D. and Bentzer, P. (2016) The Endothelial Glycocalyx and Its Disruption, Protection and Regeneration: A Narrative Review. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine, 24, Article No. 48. https://doi.org/10.1186/s13049-016-0239-y
|
[46]
|
林源希, 李真玉. 糖萼在脓毒症血管内皮损伤中的变化及其修复策略研究进展[J]. 解放军医学杂志, 2022, 47(10): 1049-1056.
|
[47]
|
Toner, P., McAuley, D.F. and Shyamsundar, M. (2015) Aspirin as a Potential Treatment in Sepsis or Acute Respiratory Distress Syndrome. Critical Care, 19, Article No. 374. https://doi.org/10.1186/s13054-015-1091-6
|
[48]
|
Shah, F.A., Meyer, N.J., Angus, D.C., et al. (2021) A Research Agenda for Precision Medicine in Sepsis and Acute Respiratory Distress Syndrome: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 204, 891-901. https://doi.org/10.1164/rccm.202108-1908ST
|
[49]
|
Zheng, F., Pan, Y., Yang, Y., et al. (2022) Novel Biomarkers for Acute Respiratory Distress Syndrome: Genetics, Epigenetics and Transcriptomics. Biomarkers in Medicine, 16, 217-231. https://doi.org/10.2217/bmm-2021-0749
|
[50]
|
Mokrá, D. (2020) Acute Lung Injury—From Pathophysi-ology to Treatment. Physiological Research, 69, S353-S366.
https://doi.org/10.33549/physiolres.934602
|